Response to Peginterferon-alfa 2b and Ribavirin in Japanese Patients with Chronic Hepatitis C Genotype 2
Response to Peginterferon-alfa 2b and Ribavirin in Japanese Patients with Chronic Hepatitis C Genotype 2
复制标题
DOI：
10.1007/s10620-011-1750-7
复制
发表时间：
2011-11-01
影响因子：
3.1
通讯作者：
Yokosuka, Osamu
中科院分区：
文献类型：
--
作者：
Kanda, Tatsuo;Imazeki, Fumio;Yokosuka, Osamu
背景目前对基因型2型丙型肝炎病毒（HCV）感染患者的标准治疗是聚乙二醇干扰素（PEG-IFN）联合利巴韦林（RBV）治疗24周。目的我们评估了与治疗持续时间相关的日本HCV基因型2型感染患者的持续病毒学应答（SVR）率。方法2006年至2009年期间，在千叶县的147名HCV基因型2感染患者中，最终纳入了138名连续患者。21例、97例和20例患者分别接受PEG-IFN-α 2b联合RBV治疗16周、24周和48周。流行病学资料和治疗结果进行了回顾性评价。结果总的SVR率为82.6%（114/138），其中初治组为86.4%（89/103），既往治疗组为71.4%（25/35）。治疗16、24和48周的患者获得的SVR率分别为66.6%（14/21）、86.5%（84/97）和80.0%（16/20）。对于部分HCV基因2型感染者，联合治疗24周可能上级16周。需要更精确的患者选择以缩短联合治疗。
Background The current standard treatment for patients infected with hepatitis C virus (HCV) of genotype 2 is the combination of peginterferon (PEG-IFN) plus ribavirin (RBV) for 24 weeks.Aims We assessed the sustained virological response (SVR) rates in HCV genotype 2-infected Japanese patients in relation to the duration of treatment.Methods Between 2006 and 2009, among 147 patients with HCV genotype 2-infection in Chiba Prefecture, 138 consecutive patients were finally enrolled. Twenty-one, 97 and 20 patients were treated with PEG-IFN-alfa 2b plus RBV for 16, 24 and 48 weeks, respectively. Epidemiological data and treatment outcomes were retrospectively evaluated. HCV RNA was measured with COBAS AMPLICOR HCV Monitor Test v. 2.0.Results The overall SVR rate was 82.6% (114 of 138): treatment-na < ve patients, 86.4% (89 of 103); patients with history of previous treatment, 71.4% (25 of 35). Patients treated for 16, 24 and 48 weeks obtained SVR rates of 66.6% (14 of 21), 86.5% (84 of 97) and 80.0 (16 of 20), respectively.Conclusions The SVR rates of PEG-IFN-alfa 2b plus RBV in Japanese patients were similar to those in previous studies. Combination treatment for 24 weeks for some patients infected with HCV genotype 2 may be superior to that for 16 weeks. More precise patient selection will be needed to shorten the combination treatment.